ton's disease is an autosomal dominant disorder a person at risk has an equal chance of inheriting an affected or unaffected chromosome from the affected parent. If identification of the affected chromosome is possible the person's prior risk of 50% can be substantially raised or lowered3 (fig 1) .
Presymptomatic testing offers obvious advantages for those given a low risk, but there are very serious implications for those given an unfavourable result, perhaps many years before symptoms are destined to appear. Potential ethical difficulties associated with such tests include the possibility of adverse psychological effects on both the subject and the family as well as the likelihood of discrimination in such matters as employment and insurance.45 Recognition of these problems prompted the drawing up of internationally agreed guidelines67 and a growing appreciation of the need for a system to monitor and regulate the tests being carried out. This led to the establishment in 1990 of the United Kingdom Huntington's Disease Prediction Consortium, and all the centres currently offering presymptomatic testing in Britain have agreed to participate. The aims of the collaborative group are (a) to promote and maintain good standards of service provision, (b) to agree a common protocol for this purpose, (c) to serve as a forum for debate, and (d) to collect data to evaluate the testing programme.
We present a survey of clinical genetic centres that are members of the consortium and an analysis of the data collected, covering the first four years ofpredictive testing.
Introduction
Huntington's disease is a progressive neurological disorder inherited as an autosomal dominant trait. The clinical features typically appear during the fourth and fifth decades of life with restlessness and involuntary movements which develop into severe chorea and dystonia with generalised motor impairment as the disease progresses. Affected subjects are prone to a wide range of psychiatric disorders together with a subcortical dementia often causing profound difficulties in the regulation of behaviour. Death occurs usually about 15-20 years after onset.
Since 1983 the availability of genetic markers closely linked to the gene for Huntington's disease has permitted presymptomatic testing for those at risk. 132 These markers are not specific to Huntington's disease but are present in the general population, and testing is therefore possible only when the pattern of the markers co-inherited with the gene in a particular family can be distinguished from those markers inherited from the unaffected side of that family. For this to be achieved DNA samples from both parents and another affected family member or a grandparent are normally the minimum requirement. As Hunting- Calculating post-test risk therefore depends on three factors: (a) the closeness of the markers which determine informativeness; (b) the number of meioses which distance the applicant from the relatives used to determine informativeness-if DNA samples from grandparents are not available, which is usually the case, other relatives such as affected uncles and aunts or siblings are frequently used, and in these circumstances the margin oferror will be greater; (c) the age of the applicant at the time of testing-the older the applicant the lower the likelihood of an individual having the Huntington disease gene. ' In view ofthe complexities it is essential that the final risk given is calculated by using a computerised program, such as MLINK.8
Results
Between 1987 and 1990, 248 presymptomatic tests were performed in the United Kingdom-two in 1987 Kingdom-two in , 42 in 1988 Kingdom-two in , 108 in 1989 Kingdom-two in , and 96 in 1990 . The number of tests completed varied widely from centre to centre. Six regional genetic centres were responsible for 192 results in almost equal proportions, the remaining 56 results (range 1-16) having been shared among 10 centres.
One hundred and fifty eight (64%) subjects tested were female and 90 (36%) male. The ages at which subjects were given results are presented in the table. The median age overall was 32-5 years (range 18-62). The median ages at which female and male subjects received results were 32 and 33 years respectively. Only seven subjects, all female, were under 20. More than a quarter of the results were given to subjects between the ages of 25 and 29 years, and 189 (76%) subjects were under 40.
Five subjects had a prior risk of 25%-that is, they had an affected grandparent and the intervening parent was not known to be clinically affected. In these circumstances the risk can be altered to only a limited extent. Two subjects had a prior risk of 36% as their parents' risk had been altered to 72% by previous testing. There may also be a process of self selection operating in people seeking presymptomatic testing. Given the low uptake of testing, quite possibly those who seek it may be unrepresentative of the at risk population as a whole. This may occur because some at risk subjects correctly perceive that they are free of subtle abnormalities becoming evident in their siblings and are thus encouraged to seek predictive testing in the expectation of a favourable result. Alternatively, it may be the result of personality factors and cognitive changes associated with the prodromal stages of the disease which reduce the motivation to be tested. Denial ofthe diagnosis and ofthe presence ofsymptoms BMJ VOLUME 304is common in affected subjects during the early stages of Huntington's disease, and it is a frequent clinical observation that at risk subjects who have maintained a high level of vigilance for symptoms throughout their lives become oblivious to these when disease onset occurs. Some presymptomatic carriers of the Huntington disease gene may therefore be less likely to seek predictive testing because early cognitive changes have made them less worried about the possibility of inheriting the disease. Conversely, others may have become aware of subtle prodromal symptoms that cannot be detected clinically and avoid testing in order to delay confrontation of this fact.
CORE PROTOCOL FOR SERVICE USE
Because of the complexity of the procedures, the need for strict diagnostic accuracy, and concern about the psychological and social consequences for those given an unfavourable prediction, one of the first tasks of the consortium was to produce a universally accepted service protocol. This states that applicants should have a confirmed family history of Huntington's disease, have a potentially informative family structure, be aged 18 years and over, and freely give informed consent. The decision whether to be tested is always the choice ofthe individual, except for limited exclusion criteria which include (a) people already clinically affected with Huntington's disease, (b) people having a serious suicidal intent, (c) people suffering from current mental illness, and (d) people for whom there is reason to believe that their mental health could be significantly impaired by testing.
Preparation for the test consists of at least two counselling sessions separated by a significant interval and conducted by two counsellors, one of whom should be medically qualified and the other an experienced genetic counsellor. Applicants should also have previously received full genetic counselling in an appropriate centre. When there is a stable relationship the partner will always be asked to participate in at least one counselling session.
At the first counselling session basic demographic information is collected and the methods and limitations of testing explained, including the need for blood samples from family members and confirmation of the diagnosis in key relatives. Applicants' knowledge of the disease, the impact of being at risk, and their motivation for taking the test are explored. The potential consequences of receiving a result are discussed, with particular reference to possible adverse effects on the applicant's mental health; marital, family, and social relationships; employment; financial and insurance conumitments; and plans. Subjects are also encouraged to consider in advance to whom the test result will be disclosed and who will provide posttest support. Written material is offered to reinforce the counselling and a neurological examination is performed at either the first or second interview.
Applicants presenting with neurological signs can be a difficult counselling problem because they are often unaware or unwilling to admit that they could already be affected. 6 Ifthe signs ofthe disease are unmistakable the tester usually suggests that the test should be postponed and a formal neurological opinion obtained when the patient is ready. An equally difficult situation can arise when the symptoms are equivocal; the experienced tester may be highly suspicious but the symptoms are insufficient to permit confirmation of the diagnosis. If the patient remains firm in the desire to be tested, after careful observation, assessment, and counselling molecular genetic testing may be performed, but this procedure can be hazardous. These patients in effect suffer a double blow: they discover not only that they are gene carriers but that they are already showing signs of the disease, and one case of serious self harm has already been reported in such a circumstance in Canada. '7 The second counselling session takes place when it is known that testing the applicant would be informative. At Likewise it is advisable to allow considerable time (usually a year) to elapse between making the diagnosis of Huntington's disease in the parent and accepting any of their offspring into the testing programme. Experience shows that people newly at 50% risk initially express great interest in having their risk refined but change their minds later when they have adjusted to their new status and have given more thought to the possible impact of an adverse result.
Conclusion
The worth of presymptomatic testing in Huntington's disease remains to be proved and requires careful follow up of subjects tested. The availability of a large body of pooled data from all the presymptomatic testing centres in the United Kingdom will form a valuable resource for monitoring the long term impact of these tests on the patients and families concerned.
Introduction
International comparisons have shown that the occurrence of coronary heart disease varies greatly from one country to another. In China the incidence of and mortality from coronary heart disease are low, as shown by, for example, the World Health Organisation monitoring trends and determinants in cardiovascular disease (MONICA) project.' The highest age standardised coronary heart disease mortality in men aged 35-64 years was found in the Siberian MONICA study (401/100 000) and the lowest in the Sino-MONICA-Beijing study (40/100000). In women the highest coronary heart disease mortality was found in the Glasgow MONICA study (132/100000) whereas in Beijing it was only 28/100 000.' These 10-fold differences in men and 4-7-fold differences in women may be explained by different levels of coronary heart disease risk factors,2 but it has also been proposed that these risk factors may have different impact on the development of coronary heart disease in different geographic areas and in genetically different populations.
There have been many studies comparing coronary heart disease risk factor levels in different countries.2-6 Genetics, ethnic background, lifestyles, and study methods have often differed between the areas, hence the possibilities for valid conclusions from many earlier comparisons are limited. The Ni-Hon-San (NipponHonolulu-San Francisco) Japanese migrant study initiated in the mid-1960s overcame many methodological shortcomings and showed a clear gradient in coronary heart disease mortality among Japanese men
